Who We Are
Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's.
The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibitor designed to potently target KIT D816V and other mutations in KIT exon 17. These mutations are known drivers of systemic mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST) - both serious conditions driven by oncogenic KIT signaling. Bezuclastinib is currently being evaluated in multiple registration-directed trials across Non-Advanced SM (NonAdvSM), Advanced SM (AdvSM), and GIST. In July 2025, Cogent announced that its registration-direct SUMMIT trial in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints, and the company is on track to file its first New Drug Application for this patient population by the end of 2025. The company also remains on track to announce top-line results for its APEX trial in patients with AdvSM in the second half of 2025 and for its PEAK trial in patients with GIST by the end of 2025. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor, and the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting other serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.
Through its commitment to precision medicine and targeted innovation, Cogent Biosciences is working to transform the treatment landscape for patients with serious and underserved diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease. Our culture of inquisitiveness fuels continuous learning and innovation; we challenge assumptions, ask bold questions, and embrace a mindset of discovery to uncover transformative insights.
The Role
The Director-Corporate Accounts-Group Purchasing Organizations (GPOs), and Strategic Partners is responsible for developing and maintaining strategic customer relationships with Specialty and Hospital GPOs (ex. ION, Onmark, Unity, and VitalSource), hospital GPOs (ex. Vizient, Premier, HPG and Apexus) and strategic partners (ex. Ontada, Cardinal Specialty Solutions) that support the Cogent strategic objectives. The role will be Cogent’s single point of call for all activities related to their assigned accounts while collaborating with Marketing, Contracting, Medical, Legal, Compliance, Commercial Ops, and other members of the Market Access team to achieve our corporate goals. The role will manage contract execution, evaluate operational efficiency, and assess the overall effectiveness of the GPO and strategic partners strategies relationships, troubleshooting issues as they arise and identify ongoing opportunities for improved ways to engage with the customer.
Responsibilities
- Engage and partner with key oncology (specialty (oncology, allergy, GIs/hospital) GPO stakeholders to develop a community and health system GPO engagement strategy.
- Develop and implement an oncology/allergy GPO contracting strategy in collaboration with cross-functional partners.
- Act as the key subject matter expert for internal stakeholders, informing all related functions on critical GPO, and strategic partner inputs, including but not limited to finance, data reporting and performance metrics.
- Lead specialty (oncology, allergy, GIs/hospital) GPOs, and strategic partner relationships as the Cogent single point of contact
- Facilitate and attend industry meetings.
- Identify issues and opportunities, developing fundamental and creative solutions to support the Brand and Market Access strategies for Bezuclastinib
- Monitor competitive landscape to recognize competitive challenges and opportunities to further differentiate Cogent relative to the competition.
- Ensure strategies and KPIs are implemented and monitored to achieve our commercial goals while working within the assigned budget.
- As needed, negotiate and establish service agreements with all assigned accounts.
- Partner with the field engagement teams (Sales/Market Access), Operations and Analytics, and Marketing to develop and implement key strategic programs and tactics to support Cogent product pull-through
Preferred Experience
- Requires bachelor’s degree, or advanced degree
- Minimum 8-10 years of account management experience with oncology/specialty clinic GPOs (ION, Onmark, Unity, & VitalSource, Premier, Vizient, HPG etc), and strategic partners (e.g.: Ontada, Cardinal Specialty Solutions, ION, NCODA, COA)
- Current relationships with key oncology/allergy GPO/provider networks (ex. Florida Cancer Specialist) stakeholders and strategic partners
- Experience with contract negotiation, implementation, execution, and performance monitoring
- Ability to travel overnight up to 50% (travel consists of working with field sales, attending business meetings, industry meetings, and working with key customers)
Qualifications
- Strong analytical acumen
- Strong presentation skills
- Oral oncology experience for a launch product required. Launch experience on behalf of a publicly traded company’s first market entry preferred
- Executive presence with a strong sense of accountability
- Proven team leadership with seamless cross-functional coordination
- Track record of efficient and effective, solution-oriented multi-tasking capability
Salary Range
$240,000 - 280,000 USD
Target Bonus: 20%
Exact compensation will vary based on skills, experience, and location.
Our Locations
Waltham, MA: Our Boston office includes an open office layout that has recently undergone a makeover designed for collaboration and giving our employees the best work place possible. Free access is provided for both on-site parking and gym facilities in the building.
Boulder, CO: We have just moved into our new state-of-the art Research Facility in the fast-growing biopharmaceutical hub in the greater Denver/Boulder corridor. Our CEO is based full-time in this location and we are proud to call this the home of Cogent’s discovery research organization.
Our Offer To You
To attract the very best talent, we offer a generous benefits package that includes competitive pay, performance-based bonus, stock options, insurance coverage (health, dental, life, and disability), competitive time-off, a 401(k) plan, and commuter/parking benefits.
We are proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability, or any other status protected under federal, state, or local law. All employment is decided on the basis of qualifications, merit, and business need.
